John Graves

New directorship holder are: (front row, from left) Jonathan Soslow, MD, MSCI; Jill Simmons, MD; Lori Jordan, MD, PhD; Janice Law, MD; Angela Jefferson, PhD; Carrie Menser, MD; Muktar Aliyu, MBBS, DrPH, MPH; Tracy Frech, MD, MSCI; Peter Embí, MD, MS, (back row, from left) Meredith Pugh, MD, MSCI; Stephen Patrick, MD, MPH, MS; Harvey Murff, MD, MPH; John Graves, PhD; Paul Sternberg Jr., MD; Joshua Robinson, OD; Fabien Maldonado, MD, MSc; Jonathan Brown, MD; Lori Ann Kehler, OD; and Julie Lounds Taylor, PhD. (photo by Donn Jones)

Directorships honor leaders, philanthropic partners

Nineteen leaders have been named as holders of directorships at Vanderbilt University Medical Center.

Health Policy lecture

Seema Verma, MPH, former administrator for the Centers for Medicare and Medicaid Services, was recently the guest of the Department of Health Policy for its Research into Policy and Practice Lecture Series.

Discussing CMS changes

Former Centers for Medicare and Medicaid Services administrator Seema Verma, MPH, was recently the guest of Vanderbilt University Medical Center’s Department of Health Policy’s Research into Policy and Practice Lecture Series.

Panel discusses current health policy landscape

The difficulty of policymaking with a divided government and electorate was the underlying theme of the Research into Policy and Practice webinar sponsored by the Department of Health Policy at Vanderbilt University Medical Center as panelists and attendees gathered virtually to take measure of the post-election American landscape, over which hangs the pall of a surging pandemic.

Tennessee areas without mask requirements have higher death toll per capita

Tennessee areas where mask requirements were instituted over the summer have substantially lower death rates due to COVID-19 as compared to areas without mask requirements, according to a new analysis by Vanderbilt Department of Health Policy researchers.

Screening younger women for hereditary cancers may be cost effective

Population-wide screening for genetic variants linked to hereditary breast and ovarian cancer may be cost effective in women between the ages of 20 and 35, according to a study published in JAMA Network Open.

1 2 3